The Food and Drug Administration recently approved Intrarosa as a treatment for women who experience dyspareunia, or moderate to severe pain during sexual intercourse.
Dyspareunia is a common symptom of vulvar and vaginal atrophy, which often occurs in women who have already undergone menopause.
Intrarosa, developed by Queben, Canada-based Endoceutics, is a once-daily vaginal insert.
The product represents the first FDA-approved treatment to contain the active ingredient prasterone, according to a press release on the agency's website.
More articles on supply chain:
Gavis Pharma earns FDA approval for generic painkiller
Amazon sues sellers for allegedly bogus products
Study: Generic heart drugs vary widely in price, limit access to uninsured patients